Conference Summaries: Day Two<BR> Tuesday, July 11, 2000

The Body Covers: The XIII International AIDS Conference

Conference Summaries: Day Two
Tuesday, July 11, 2000

Search through Durban conference original abstracts at the U.S. National Library of Medicine

Plenary Session: Living with AIDS
Coverage by Calvin Cohen, M.D.
Post-Exposure Prophylaxis (PEP)
Coverage by Judith Currier, M.D.
- Treatment of sexual assault. A multicenter study in emergency medico-legal units in the Paris region (TuOr314)
- Prophylaxis after non-occupational HIV exposure: an overview of the policies implemented in 27 European countries (TuOrC316)
New Antivirals/Targets
Coverage by Judith Currier, M.D.
- New second-generation NNRTIs: improved resistance and cross-resistance profiles (TuPpA1145)
- Anti-HIV activity and tolerability of DAPD, a novel dioxolane guanine RT inhibitor: preliminary results of a phase I/II clinical trial (TuPpA1146)
Adherence to Antiretroviral Therapy -- Why So Low?
Coverage by Alvan Fisher, M.D.
- Nonadherence to triple-combination ART is predictive of AIDS progression and death in HIV+ men and women (TuOrB419)
- Low frequency of genotypic resistance markers in therapy-naive HIV+ adolescents (TuPeA3007)
The Prevalence of Hypogonadism in HIV-Infected Patients Receiving HAART (Poster Presentation TuPeB3180)
Coverage by Alvan Fisher, M.D.
Behavioral Predictors and Outcomes of HAART
Coverage by Calvin Cohen, M.D.
- Poorer adherence to HAART and risky sex behavior within HIV-serodiscordant couples (TuOrD335)
Attempts at Simplifying Treatment Regimens
Coverage by Calvin Cohen, M.D.
- The ADAM study: maintenance therapy after 50 weeks of induction therapy (Poster Presentation TuPpA1154)
- Once-a-day indinavir therapy in virologically controlled HIV-positive persons (Poster Presentation TuPpA1155)
ARV Clinical Trials -- II
Coverage by Calvin Cohen, M.D.
More on Salvage Studies
Coverage by Judith Feinberg, M.D.
- ABT-378/ritonavir and efavirenz for salvage therapy in patients multiply-exposed to PIs (TuPeB3196)
Safety and Efficacy of Abacavir and Efavirenz
Coverage by Judith Feinberg, M.D.
- PROTRA study: To evaluate the safety and efficacy of abacavir (ABC) and efavirenz (EFV) when substituted for a PI in HIV-1-infected subjects treated with two NRTIs and a PI with plasma HIV-RNA levels below the limit of assay quantification (Poster, TuPeB3210)
Mitochondrial Toxicity
Coverage by Calvin Cohen, M.D.
Debate: Affordable Drugs, Antiretroviral Therapy
Coverage by Calvin Cohen, M.D.
- Debate: Until there are more affordable drugs, antiretroviral therapy less than HAART is acceptable in developing countries (TuOr52-53)
Reverse Transcriptase (RT) Mutation Patterns from ZDV-Naive Subjects Failing d4T-Containing Regimens (Poster, TuPeA3014)
Coverage by Calvin Cohen, M.D.
Pharmacokinetics of Amprenavir (APV) in Combination with Efavirenz (EFV) or Delavirdine (DLV) in HIV-Infected Children (Poster, TuPeB3296)
Coverage by Calvin Cohen, M.D.
Therapeutic Drug Monitoring of Amprenavir Combined with Ritonavir as Salvage Therapy in HIV-1-Infected Patients (Poster, TuPeB3305)
Coverage by Calvin Cohen, M.D.
HIV-Related Malignancies
Coverage by Judith Feinberg, M.D.
- Emergence of oral HPV infection among HIV-infected patients in the HAART era (TuOrB304)

Return to The Body's coverage of
The XIII International AIDS Conference.

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.